LEXINGTON, Mass.--(BUSINESS WIRE)--Sept. 20, 2006--EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX) today announced that the Australian Therapeutic Goods Administration (TGA) has approved its novel blood pool imaging agent Vasovist(TM) for marketing in Australia. Vasovist is indicated for contrast-enhanced magnetic resonance angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease.
